MK-677 (Ibutamoren / Nutrobal) is an orally bioavailable, non-peptide ghrelin mimetic that acts as a potent agonist at the growth hormone secretagogue receptor (GHSR-1a). Unlike growth hormone itself or peptide secretagogues, MK-677 achieves sustained GH and IGF-1 elevation through oral administration — a significant distinction for research applications.
MK-677 mimics the action of ghrelin at the GHSR-1a receptor in the hypothalamus and pituitary. This stimulates pulsatile release of growth hormone from the anterior pituitary. The resulting GH elevation subsequently drives hepatic IGF-1 production, creating anabolic and metabolic effects that differ mechanistically from direct androgenic signalling.
Crucially, MK-677 does not activate the androgen receptor and does not suppress endogenous testosterone production. This distinguishes it fundamentally from SARMs and anabolic steroids from a mechanistic standpoint. However, elevated GH and IGF-1 do have anabolic effects on muscle and bone, making MK-677 of research interest in conjunction with or independent of AR-targeting compounds.
MK-677 also stimulates appetite (via ghrelin mimicry), increases cortisol, and is associated with transient insulin resistance at higher doses — all relevant variables in research protocol design.
Multiple published trials document MK-677's pharmacodynamic effects in humans. Murphy et al. (1998, Journal of Clinical Endocrinology & Metabolism) investigated MK-677 in 65-year-old adults over 2 years, demonstrating sustained increases in GH pulsatility, IGF-1 levels, and improvements in bone mineral density. The trial also documented fat-free mass preservation in older subjects.
Nass et al. (2008) studied MK-677 in GH-deficient adults, confirming IGF-1 restoration comparable to GH replacement. Svensson et al. (1998) demonstrated improvements in sleep quality in young volunteers — consistent with GH's role in slow-wave sleep architecture. Chest et al. (2004) documented lean mass gains and fat mass reduction in obese subjects over 8 weeks.
Technically, no. MK-677 does not bind to the androgen receptor. It is a growth hormone secretagogue. However, it is frequently grouped with SARMs in the research chemical space due to overlapping research applications and the anabolic effects of GH/IGF-1 elevation.
No. Because MK-677 acts via GHSR-1a rather than the androgen receptor, it does not suppress the HPT (hypothalamic-pituitary-testicular) axis. Post-cycle support specifically targeting testosterone recovery is not required after MK-677 alone, though elevated cortisol is a consideration.
Published data documents: sustained GH and IGF-1 elevation; improvements in lean body mass; reductions in fat mass (particularly visceral fat in some trials); improved bone mineral density; enhanced slow-wave sleep quality; appetite stimulation; and transient insulin resistance at higher doses.
Published human trials have run up to 2 years (Murphy et al. 1998). Research protocols typically range from 12–24 weeks, with some researchers running MK-677 continuously given its non-suppressive nature. Longer durations allow for the full bone density and body composition effects to manifest.
